近距放疗联合间歇性内分泌治疗在前列腺癌治疗中的应用

The joint application of brachytheraphy and intermittent hormonal therapy in treating prostate cancer

目的:分析比较125I粒子植入近距放疗联合间歇性内分泌治疗在前列腺癌治疗中的效果。方法:回顾2001年1月～2011年2月期间未接受根治性前列腺切除而接受治疗满5年的147例前列腺癌患者,按治疗方式分为三组;A组43例单纯采用间歇性内分泌治疗;B组31例单纯采用近距离125I粒子植入;C组73例施行近距离125I粒子植入+间歇性内分泌治疗。比较三组患者的临床症状、PSA变化情况、局部进展率、无事件生存率。结果:147例患者,A组5年生存率为88.37%,无效率13.95%,无事件生存率16.28%;B组生存率为90.32%,无效率22.58%,无事件生存率32.26%;C组生存率为90.41%,无效率6.85%,无事件生存率34.25%。结论:近距离125I粒子植入+间歇性内分泌联合治疗作为前列腺癌的综合治疗手段,可以提高无事件生存率、增加治疗有效率、缩短内分泌治疗时间。

Objective：Analysis and comparison of ^125I seed implantation and intermittent endocrine therapy for prostate cancer. Method： Between January 2001 and February 2011, The clinic records of 147 men with prostate carcinoma who had not received radical prostatectomy, were divided into 3 groups according to the treatment： Group A consists of 43 cases that received simple use of intermittent endocrine therapy; Group B consists of 31 pa tients who received ^125I brachytherapy; Group C contains 73 patients who underwent ^125I brachytherapy plus inter- mittent endocrine therapy. To compare with the three groups include clinical symptoms, PSA changes, local pro- gression rate,and event-free survival. Result： 147 cases were followed up ≥5 years. Group A 5-year survival rate was 88. 37%,13.95% inefficiency, event-free survival rate was 16.28%; Group B survival rate was 90.32%, 22.58% inefficiency, event-free survival rate was 32.26%; Group C survival rate was 90.41%, inefficiency of 6.85 %, event-free survival rate of 34.25 %. Conclusion;The close-125I seed implantation and intermittent hormonal therapy as a comprehensive treatment of prostate cancer can improve event free survival, increase treatment effi- ciency, shorten time to endocrine therapy.